Refine by
Neurodegenerative Articles & Analysis
187 news found
This compound has gained attention for its multifunctional properties and critical role in drug discovery and development.N-Benzylhydroxylamine Hydrochloride features a unique nitrogen–oxygen (N–O) functional group, which enables its wide-ranging applications in medicinal chemistry, including:l Metal Chelation for Iron Overload Disorders: Its ability to form stable complexes with metal ions like ...
Researchers have long recognized the importance of CCM in regulating cellular function and contributing to the understanding of various diseases, including cancer, diabetes, and neurodegenerative disorders. However, traditional methods of analyzing these complex metabolic networks have often fallen short, hindering progress in the field. ...
These include E3 ligase ligands such as CRBN and VHL, and linkers which act as a mediator between target proteins and ligases to broaden the therapeutic options (especially in the treatment of cancer and neurodegenerative diseases). Nucleosides, the building blocks of nucleic acids, aren’t only simple building blocks for RNA and DNA. ...
This comprehensive offering provides researchers with a powerful tool for studying various neurological disorders, including brain tumors, head and neck cancers, and neurodegenerative diseases. For example, Multiple Sites of Normal Brain Tissue Microarray, 80 Cases, 26 Cores (Catalog NO. ...
Neuroscience: The exploration of the roles played by 5mC and 5hmC in neurodevelopment and neurodegenerative diseases holds the promise of revealing new therapeutic targets. ...
Cognitive behavioral tests have wide applications in understanding neurodegenerative diseases and non-neurological disorders that often lead to cognitive dysfunction. ...
Depression is commonly seen in neurodegenerative and neurodevelopmental diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and autism spectrum disorders. ...
The symptoms of these disorders can vary widely and may include muscle weakness, neurodegenerative disorders, vision and hearing loss, and metabolic disorders. ...
Similar innovations in regenerative medicine and stem cell therapy are likewise opening the way for potentially revolutionary treatments of degenerative eye diseases, heart disease, and neurodegenerative disorders. Read more ...
Mitochondria dysfunction has been tied to a host of diseases, ranging from neurodegenerative ailments, over heart attacks and strokes, to age-related degeneration. ...
A five-year action plan developed to meet requirements under Section 4 of the Accelerating Access to Critical Therapies for ALS Act. ...
Building upon our notable preliminary results, we look forward to the continued development of anle138b alongside Teva to help patients living with currently untreatable neurodegenerative diseases, including MSA, PD and Alzheimer’s disease. With the introduction of small-molecule medication, we open a new chapter in the fight against neurodegenerative ...
Bioactive lipids are consistently involved in chronic inflammation for pathological characterization, such as cancer, diabetes, atherosclerosis, asthma, inflammatory bowel disease, as well as autoimmune and neurodegenerative disorders. “With years of experience in lipid chemistry, Alfa Chemistry now provides a full range of fatty acids and esters, glycerides, fatty ...
Phase 1 trial of tau-targeting lead program planned to begin in 3Q22 Funding will also support the characterization of the Company’s second-generation assets Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, announced that the Company has ...
Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for Alzheimer’s and rare neurodegenerative diseases, announced that the Company presented data from a therapeutic study in an animal model of its lead product candidate OLX-07010 at the 14th Annual Clinical Trials on Alzheimer's Disease (CTAD) conference and at ...
Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, today announced that the U.S. ...
Its most advanced program BRT-DA01 is being developed for the treatment of Parkinson’s disease, a progressive neurodegenerative disorder caused by nerve cell damage in the brain. It comprises of pluripotent stem cell-derived dopaminergic neurons that are implanted into the brain, thus taking target at the root cause of the disease. ...
ByBayer AG
The technology is designed to advance treatments for neurodegenerative diseases, including therapies with complex molecules such as monoclonal antibodies and larger peptides, by allowing medication to cross the blood-brain barrier and access the most penetrable part of the blood-brain barrier at the top of the nasal cavity. ...
Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, today announced the presentation of IND-enabling preclinical data on its lead product candidate OLX-07010 at the annual Clinical Trials on Alzheimer's Disease (CTAD) and Society for Neuroscience’s ...
“We are excited to advance ET-101, our novel treatment for neurodegenerative diseases, towards a first-in-human clinical trial in ALS patients. ...